

<!--StartFragment-->RESULT 8

AAR78746

ID AAR78746 standard; peptide; 4 AA.

XX

AC AAR78746;

XX

DT 25-MAR-2003 (revised)

DT 05-OCT-1995 (first entry)

XX

DE Glycosylated haemoglobin immunogenic tetrapeptide.

XX

KW Glycosylated haemoglobin; HbA1c; HbS1c; HbC1c; immunoassay; hapten;

KW immunogen; simultaneous detection; haemoglobinopathy;

KW sickle cell anaemia; diabetes mellitus; disease monitoring.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "Fructose-Val"

XX

PN EP598329-A2.

XX

PD 25-MAY-1994.

XX

PF 11-NOV-1993; 93EP-00118251.

XX

PR 17-NOV-1992; 92DE-04238705.

PR 31-MAR-1993; 93DE-04310500.

XX

PA (BOEF) BOEHRINGER MANNHEIM GMBH.

PA (HOFF) ROCHE DIAGNOSTICS GMBH.

XX

PI Karl J. Finke A, Engel W;

XX

DR WPI; 1994-219495/27.

XX

PT New antibodies for simultaneous determ. of different forms of

PT glycosylated haemoglobin - for diagnosis and monitoring of diabetes and

PT haemo-globin-opathy, e.g. sickle cell anaemia.

XX

PS Claim 1; Page 11; 12pp; German.

XX

CC The present glycosylated oligopeptide is used as an immunogen to generate
 CC antibodies which recognise glycosylated-haemoglobin HbA1c and its
 CC variants HbS1c and HbC1c. The new antibodies allow simultaneous detection
 CC of all three forms of haemoglobin. Determination of glycosylated Hb gives
 CC an indication of long term blood glucose levels for monitoring diabetes
 CC mellitus or haemoglobinopathy such as sickle cell anaemia. (Updated on 25
 CC -MAR-2003 to correct PN field.) (Updated on 25-MAR-2003 to correct PA
 CC field.)

XX

SQ Sequence 4 AA;

Query Match 100.0%; Score 12; DB 2; Length 4;

Best Local Similarity 100.0%; Pred. No. 2.1e+06;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 VH 2

||

Db 1 VH 2

<!--EndFragment-->